There were 1,122 press releases posted in the last 24 hours and 400,916 in the last 365 days.

T3 Pharmaceuticals Wins Prestigious Falling Walls Venture Award for Its Bacterial Cancer Therapy

T3 Pharma logo

Basel, Switzerland, November 09, 2018 / B3C newswire / -- T3 Pharmaceuticals (“T3 Pharma”), a biotech company with a focus on immuno-oncology, today announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models.

The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists to identify trends, opportunities and solutions for global challenges and discover international breakthrough research. Falling Walls Venture showcases the most promising research based start-ups from all over the globe that tear down walls and overcome boundaries in their respective fields.

“We are honored to receive this prestigious award. We thank the jury for recognizing the medical potential of our immuno-oncology approach. Our sincerest thanks go to all our friends, partners and supporters and, particularly, to the University of Basel, who nominated us for this award”, commented Dr. Simon Ittig, CEO of T3 Pharma. “The Falling Walls Venture Award confirms our aspirations to advance our therapy into clinical use for the benefit of cancer patients.”

T3 Pharma’s engineered bacteria stimulate the immune system by delivering selected human proteins directly into cells of the tumor microenvironment. Preclinical studies in a number of tumor models demonstrated a strong impact on tumor progression as well as a durable immune-mediated memory to fight recurring tumors. The clinical development for the lead candidate has been initiated in order to assess the immunotherapy in men with a first clinical trail anticipated for the first half of 2020.

About T3 Pharma T3 Pharmaceuticals was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The company is focusing on bacteria-based therapies for the treatment of solid tumors.


T3 Pharma Dr. Simon Ittig, CEO +41 61 207 20 74

TS Kommunikation Thomas Staffelbach +41 79 541 38 31

Posted by Sabine Duntze, B3C Group GmbH and shared through Newronic®